ADAG stock forecast, quote, news & analysis
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies... Show more
Why Adagene (ADAG) Stock Is Down -19% in the Last 30 Days
Key Takeaways
- ADAG shares fell roughly 19% over the trailing 30 days, closing at $2.58 on October 27, 2026, down from $3.20 on September 28.
- The decline extends a longer pullback: the stock is down about 31% from its late-July level near $3.73 after peaking around $4.23 in early August.
- The sharpest leg occurred between October 12 and October 16, when the stock dropped from $2.74 to $2.06.
- The slide unfolded despite reiterations of Buy ratings and $7.00 price targets from H.C. Wainwright and Stifel on October 19.
- No single company-specific announcement appears to explain the move, pointing to sentiment-driven selling and profit-taking in a volatile, pre-revenue biotech.
- The investment case remains anchored to muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody with FDA Fast Track designation in microsatellite-stable (MSS) colorectal cancer.
- For deeper context, review Adagene's Price Targets, Earnings, and Forecast on additional analysis pages.
- Explore Trending AI Robots to see how automated strategies are currently approaching momentum across the market.
Adagene (ADAG) Company Overview and Market Position
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company headquartered in San Diego, California, and Suzhou, China. It combines computational biology and artificial intelligence to design novel antibody-based cancer immunotherapies. The company's proprietary Dynamic Precision Library (DPL) platform comprises three technologies: NEObody, SAFEbody precision masking, and POWERbody, which support a differentiated pipeline of immunotherapy programs.
Adagene's lead candidate, muzastotug (ADG126), is a masked anti-CTLA-4 SAFEbody that received FDA Fast Track designation in combination with pembrolizumab for adult patients with MSS metastatic colorectal cancer without active liver metastases. The company has built strategic collaborations with major pharmaceutical partners, including Sanofi, Exelixis, Roche, and Merck, and with emerging biotechs such as Third Arc Bio and ConjugateBio. As of December 31, 2025, Adagene reported unaudited cash and cash equivalents of $74.5 million, which it expects will fund operations into late 2027.
Adagene (ADAG) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, ADAG fell from a closing price of $3.20 on September 28, 2026, to $2.58 on October 27, 2026, a decline of roughly 19%. The move was not linear: the stock traded near $3.20 into late September before grinding lower through early October, then accelerating sharply between October 12 and October 16, when it fell from $2.74 to $2.06. Shares have since partially recovered, finishing around $2.58.
The 30-day slide is part of a broader multi-month retreat. After rallying to a peak near $4.23 in early August, ADAG has shed about 31% from its late-July level near $3.73. The pattern reflects a stock that gave back a sharp summer rally and has remained under sustained selling pressure into the autumn, despite a lack of obvious negative company-specific news.
What Drove ADAG Stock Price in the Last 30 Days
The October decline in ADAG appears to have been driven primarily by market sentiment rather than a single disclosed corporate event. The company's public disclosures during the period were generally constructive: Adagene announced participation in the H.C. Wainwright Immune Cell Engager Virtual Conference on October 15 and the Guggenheim Securities Healthcare Innovation Conference in November. On October 19, H.C. Wainwright reiterated its Buy rating with a $7.00 price target, and Stifel set a $7.00 price target on the stock.
That the shares fell despite these reiterated bullish views suggests the move was led by profit-taking after the early-August rally, thin trading liquidity, and broader pressure on small-cap and pre-revenue biotechnology names. With no near-term data readout scheduled during the period, momentum and sentiment appear to have been the dominant drivers, underscoring the elevated volatility typical of clinical-stage biotech equities.
What Drove ADAG Stock Performance Over the Last Quarter
Over the trailing three months, ADAG's trajectory has been a steady fade from its early-August highs. The stock's summer strength reflected investor enthusiasm around muzastotug's clinical progress, FDA Fast Track designation, and a deepening roster of partnerships, including Sanofi's up-to-$25 million strategic investment and collaboration milestones with Exelixis and Third Arc Bio. In September, Adagene announced a preclinical milestone payment from Exelixis for its SAFEbody antibody-drug conjugate program and the selection of a first lead candidate under its amended Third Arc Bio collaboration.
However, without a major data catalyst to sustain the rally, the stock drifted lower through September and October as early gains were consolidated. The quarterly move highlights how clinical-stage biotech valuations can swing sharply on positioning and sentiment between data readouts, even when the underlying pipeline news remains broadly positive.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's artificial-intelligence trading bots. Tickeron offers hundreds of AI-driven bots that trade thousands of tickers, but only top-performing and most relevant strategies are featured in this section. Each bot operates with its own strategy, timeframe, and performance metrics, ranging from short-term momentum approaches to longer-horizon swing systems. For investors tracking volatile names such as ADAG, these tools provide an additional lens on how automated, rules-based strategies respond to changing market conditions. Visitors can browse the section to compare bot performance and explore whether algorithmic trading aligns with their own research process.
ADAG Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important catalysts for ADAG center on muzastotug. Investors are monitoring updated overall survival and duration-of-response data from the Phase 1b/2 study of muzastotug in combination with pembrolizumab in MSS colorectal cancer, as well as progress on enrollment in the randomized Phase 2 dose-optimization study. Additional readouts from the Roche-sponsored triplet combination in first-line hepatocellular carcinoma and the Sanofi-sponsored combination trial could further shape the pipeline narrative.
Beyond clinical data, key factors include the pace of partnership and licensing activity, cash management against the company's runway into late 2027, and the broader risk appetite for pre-revenue biotech and China-based issuers. Analyst consensus remains Buy-rated, but meaningful share-price recovery will likely depend on new clinical data or partnership milestones rather than sentiment alone.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ADAG sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for ADAG moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ADAG as a result. In 90 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for ADAG turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 41 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADAG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ADAG entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ADAG's RSI Oscillator exited the oversold zone, 25 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +5.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADAG advanced for three days, in 181 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
ADAG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.501) is normal, around the industry mean (3.498). P/E Ratio (-5.333) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (17.606) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. ADAG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADAG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology